We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
38.00 | 2.02% | 1,918.50 | 1,925.00 | 1,927.00 | 1,937.50 | 1,887.50 | 1,903.00 | 504,022 | 16:35:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 190M | 0.8594 | 22.41 | 4.26B |
Date | Subject | Author | Discuss |
---|---|---|---|
14/3/2018 08:37 | From memory these have been well over £20 not too long ago - so I guess, market thinks its already in the price. Anyway,here's a summary. - Hikma reported an operating loss of $747m in 2017 compared with a operating profit of $302m the previous year as increased competition in its US market weighed on its generics business. Hikma's generics business reported an operating loss of $1,082m in 2017, largely due to the $1,070m impairment of the West-Ward Columbus business. This came as the firm reduced its expectations for the West-Ward Columbus marketed portfolio and pipeline amid increased pricing pressure. 'The increasingly competitive dynamics of the US market, including intense pricing pressure, had a material impact on our Generics business and, in particular, on West-Ward Columbus, the firm said. Hikma reported a loss before tax of $738m in 2017, down 451% while core profit before tax was $328m, down 9% compared to 2016. Operating cash flow rose to $443m in 2017, compared with $293m in 2016. Group revenue was $1.94bn, down from $1.95bn the previous year. Global injectables revenue declined by 1% to $776m. In constant currency, global Injectables revenue was in line with 2016. Generics revenue was $615m in 2017, up from $604m in 2016. Branded revenue was $536m, down 4% compared with $556m in 2016 as good growth in Egypt, the GCC and Sudan, partially offset by more challenging operating conditions in other markets. The firm said it expect injectables revenue in 2018 will be in the range of $750m to $800m, while generics revenues will be in the range of $550m to $600 and core generics operating margin in the low single digits. Said Darwazah, Executive Chairman of Hikma, said: 'We delivered a solid performance in 2017 at a challenging time for our industry, demonstrating the benefit of our diversified business model. Profitability in our Branded business remained stable and our Injectables business was resilient, maintaining strong profitability despite new competitors for our top products and benefiting from our strong market position in the US hospital segment.' 'The increasingly competitive dynamics of the US market, including intense pricing pressure, had a material impact on our Generics business and, in particular, on West-Ward Columbus. This was further impacted by the delay in approval for our generic version of Advair Diskus. As a result of these headwinds, we have had to take an impairment related to the West-Ward Columbus business to reflect our updated view of the fair value of this business.' | broadwood | |
14/3/2018 08:26 | Calling the bottom? | r ball | |
14/3/2018 08:02 | Well I was expecting a huge drop on that impairment charge...but we have been pushed up sharply in the opening auction Currently uncrossing at 943!! WTF is going on? | nav_mike | |
14/3/2018 07:58 | FTSE 250-listed Hikma Pharmaceuticals reported revenue of USD1.94 for 2017, down from USD1.95 in 2016, as the drugmaker swung to a reported pretax loss of USD738 million from a profit of USD210 million.The company took a USD920 million charge in the year related to the impairment of West-Ward Columbus' intangible assets. Before exceptional items, profit still fell 9% to USD328 million from USD359 million. Hikma proposed a full-year dividend of 34 cents per share, up from 33 cents the year beforeThe company said it expects Generics revenue to be between USD550 million to USD600 million in 2018, and core operating margin in the low single digits before adjusting for lower depreciation related to the impairment taken in 2017. Generics revenue in 2017 totaled USD615 million, up from USD604 million in 2016.Injectables revenue in 2018 will be in the range of USD750 million to USD800 million, compared to a USD776 million reported for 2017 which was down 1% on 2016, as increased competition in the US is offset by new launches and continued growth in the MENA and Europe."We delivered a solid performance in 2017 at a challenging time for our industry, demonstrating the benefit of our diversified business model," said Hikma Executive Chairman Said Darwazah. | mj19 | |
14/3/2018 07:56 | oh dear..bottom line is smashed. Expect sharp drop | sandeep67 | |
14/3/2018 07:41 | What will happen today after these results ? | gerrym two | |
12/3/2018 16:42 | Certainly could have been worse today - the drop was no worse than daily noise of the last few weeks. Hopefully they can come up with a decent set of results, and paint a rosy picture going forward | nav_mike | |
12/3/2018 09:33 | Share price reaction could have been worse. No point in selling at the bottom, if indeed it should prove so. | broadwood | |
12/3/2018 08:37 | 2 year delay | r ball | |
12/3/2018 08:31 | This is old news. Just new detail. At least now we know where we are with the FDA. New trial will/should produce the expected results. Bit disappointed it's going to take so long though. As said above, fingers crossed for a decent set of results. | bantam175 | |
12/3/2018 08:07 | Oh well at least if the results are half-decent on Wednesday they wont get tarnished by the news we've had today - markets will have digested the implications by then | nav_mike | |
12/3/2018 08:04 | That bid story: Copycat drug makers on alert as Germany's Stada eyes acquisition spree "Mr Albrecht was tight-lipped on a UK target but City analysts suggested that beleaguered London-listed firms Vectura and Hikma could fit the bill – two companies developing generic drugs, products with expired patents." | kamitora | |
12/3/2018 07:52 | A bid would suit me. Suet | suetballs | |
12/3/2018 07:49 | Bad news, heading South I fear. How much is in the price? It has had a spectacular fall. | broadwood | |
12/3/2018 07:34 | Jeez...perfect timing to nullify the potential bid story in the Telegraph at the weekend Ho hum | nav_mike | |
12/3/2018 07:24 | For sure that will the share price but I think it will recover quickly | sandeep67 | |
12/3/2018 07:20 | Original FDA decision upheld. Hikma to do further work with Advair possibly by early 2019. | sza2002 | |
01/3/2018 19:07 | The market ignoring Barclays on HIK - Sweet! - Do these brokers make it up as they go along? (It's a bit like listening to the Horse Racing punters!) Is there really any credibility in what they have to say? If so, why are there so many varying opinions from different brokers? Would they not all agree on a company's fundamentals and trading position and paint a similar outlook? Been trading over 25 years, I'm still not smart enough to work this one out!! :-/ HIK were tipped several times over Christmas & New Year. Is this a broker looking for discounted prices and wishing to grab a bargain? Then ramp it up from a Sell, to a Hold, to a Buy?.. ...They're all in pole position to do this after all! | nickg100 | |
01/3/2018 16:58 | Flippin eck what happened here today? Went out this morning with price at 825 after the Barclays downgrade, and come back to 871 and blue on the day... Im sure there were people trading with knowledge of the downgrade yesterday....the BOTs were absolutely relentless all day - or maybe im just too cynical...nah! | nav_mike | |
01/3/2018 09:13 | I bought in here at £20 last year thinking I got a good price ? keep the faith people I'm still hopeful | gozzy90 | |
01/3/2018 08:31 | I feel ur pain bro , my avg now about a tenner , ho hum. | death by donut | |
01/3/2018 08:23 | Remind me to thank Barclays after I topped up yesterday - another inspired purchase :) | nav_mike | |
01/3/2018 08:09 | Barclays downgrades to 800p target from 1500. What they gonna say after results? | bantam175 | |
27/2/2018 17:28 | Fingers crossed then; anything along those lines would be welcome. | fhmktg |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions